Orphan Products Development

“The FDA’s Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouroniumdiethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period.”
© 2022 Trioxbio. All Rights Reserved

S-ethylisothiouronium diethylphosphate

“The FDA’s Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouroniumdiethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period.-“

© 2022 Trioxbio. All Rights Reserved

Symptomatic hypotension

“The FDA’s Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouroniumdiethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period.”
© 2022 Trioxbio. All Rights Reserved